<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03399227</url>
  </required_header>
  <id_info>
    <org_study_id>1713/2017</org_study_id>
    <nct_id>NCT03399227</nct_id>
  </id_info>
  <brief_title>Liver Transplantation: Skeletal Effects</brief_title>
  <official_title>Skeletal Effects of Liver Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Fifty patients awaiting liver transplantation and 50 age and gender matched control subjects
      with normal liver function will be included in the study. The aim of this project is to
      compare liver transplantation recipients'bone microarchitecture with healthy controls and to
      evaluate patients' changes within one year after transplantation
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background: Solid organ transplantation recipients have a high prevalence of osteoporosis and
      fragility fractures. Deteriorated bone architecture has been shown by high resolution
      computed tomography (HR-pQCT) in kidney and lung transplantation recipients. In liver
      transplantation (LeTx) recipients, bone microarchitecture has only been evaluated using the
      trabecular bone score in a retrospective cohort study; a degraded or partially degraded
      microarchitecture was detected in most of the patients.

      Aim: The aim of this project is to compare LeTx recipients' bone microarchitecture with
      healthy controls and to evaluate patients' changes within one year after transplantation.

      Methods: HR-pQCT scans of the distal radius and tibia as well as areal bone mineral density
      measurement of the lumbar spine and hip region will be performed before Tx, 1 and 12 months
      after Tx in 50 patients. Anabolic and catabolic markers of bone turnover (sclerostin,
      dickkopf 1, periostin) and traditional bone turnover markers will be evaluated
      preoperatively, on the day of surgery, and 4 times within the first year after LeTx. In
      healthy age- and sex-matched controls HR-pQCT, bone mineral density and laboratory parameters
      will be assessed once.

      Hypotheses: Based on the HR-pQCT data of kidney and lung transplantation recipients and the
      trabecular bone score of LeTx recipients, the investigators hypothesize that LeTX recipients
      have deteriorated bone microarchitecture.

      Expected outcome: Since bone fragility is not only determined by BMD but bone architecture as
      well, HR-pQCT data give important information on the patients' bone fragility. The knowledge
      of the course of bone microarchitecture after liver transplantation may help to develop
      strategies preventing fragility fractures in LeTx recipients.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 1, 2018</start_date>
  <completion_date type="Anticipated">March 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Bone microarchitecture of the distal radius</measure>
    <time_frame>12 months to posttransplantation</time_frame>
    <description>trabecular bone mineral density measurement (XCT)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bone microarchitecture of the distal radius</measure>
    <time_frame>pretransplantation to 12 after transplantation</time_frame>
    <description>bone volume fraction (%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone microarchitecture of the distal radius</measure>
    <time_frame>pretransplantation to 12 after transplantation</time_frame>
    <description>trabecular homogeneity (mm)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone microarchitecture of the distal radius</measure>
    <time_frame>pretransplantation to 12 after transplantation</time_frame>
    <description>trabecular number (mm-1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone microarchitecture of the distal radius</measure>
    <time_frame>pretransplantation to 12 after transplantation</time_frame>
    <description>trabecular thickness (mm)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone microarchitecture of the distal radius</measure>
    <time_frame>pretransplantation to 12 months after transplantation</time_frame>
    <description>trabecular separation (mm)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Bone mineral density</measure>
    <time_frame>pretransplantation to 12 after transplantation</time_frame>
    <description>areal bone density measurement of the lumbar spine (T score)</description>
  </other_outcome>
  <other_outcome>
    <measure>Bone mineral density</measure>
    <time_frame>pretransplantation to 12 after transplantation</time_frame>
    <description>areal bone density measurement of the hip region (T score)</description>
  </other_outcome>
  <other_outcome>
    <measure>Biochemical</measure>
    <time_frame>pretransplantation to 12 after transplantation</time_frame>
    <description>Serum levels of osteocalcin</description>
  </other_outcome>
  <other_outcome>
    <measure>Biochemical</measure>
    <time_frame>pretransplantation to 12 after transplantation</time_frame>
    <description>Serum levels of bone-specific alkaline phosphatase</description>
  </other_outcome>
  <other_outcome>
    <measure>Biochemical</measure>
    <time_frame>pretransplantation to 12 after transplantation</time_frame>
    <description>Serum levels of procollagen type 1 amino-terminal propeptide</description>
  </other_outcome>
  <other_outcome>
    <measure>Biochemical</measure>
    <time_frame>pretransplantation to 12 after transplantation</time_frame>
    <description>Serum levels of tartrate resistant acid phosphatase</description>
  </other_outcome>
  <other_outcome>
    <measure>Biochemical</measure>
    <time_frame>pretransplantation to 12 after transplantation</time_frame>
    <description>Serum levels of carboxy-terminal collagen crosslinks</description>
  </other_outcome>
  <other_outcome>
    <measure>Biochemical</measure>
    <time_frame>pretransplantation to 12 after transplantation</time_frame>
    <description>Serum levels of dickkopf 1</description>
  </other_outcome>
  <other_outcome>
    <measure>Biochemical</measure>
    <time_frame>pretransplantation to 12 after transplantation</time_frame>
    <description>Serum levels of periostin</description>
  </other_outcome>
  <other_outcome>
    <measure>Biochemical</measure>
    <time_frame>pretransplantation to 12 after transplantation</time_frame>
    <description>Serum levels of sclerostin</description>
  </other_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Liver Diseases</condition>
  <condition>Transplant-Related Disorder</condition>
  <condition>Osteoporosis</condition>
  <arm_group>
    <arm_group_label>Liver transplantation recipients</arm_group_label>
    <description>Venipuncture (6x) Bone mineral density measurement: lumbar spine, hip region (3x) high resolution peripheral quantitative CT: radius, tibia (3x)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <description>Venipuncture (1x) Bone mineral density measurement: lumbar spine, hip region (1x) high resolution peripheral quantitative CT: radius, tibia (1x)</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      venous blood samples
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        50 patients awaiting liver transplantation and 50 age and gender matched healthy controls
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women, men awaiting liver Transplantation

          -  20-70 years of age

        Exclusion Criteria:

          -  Subjects with a history of prior solid organ transplantation

          -  Subjects awaiting a combined liver-kidney transplantation

          -  Cancer within the previous 5 years - except for hepatocellular carcinoma,
             neuroendocrine tumors and hemangioendothelioma with indication for liver
             transplantation

          -  Rheumatoid arthritis

          -  Severe renal insufficiency (chronic kidney disease IV, V)

          -  Immobilisation

          -  Intake of drugs with potential effects on BMD like lithium, estrogen-replacement
             therapy, selective Estrogen-receptor modulators, oral bisphosphonates in the last
             three months, denosumab and parenteral bisphosphonates in the last year - except
             calcium, vitamin D and medication necessary for the underlying disease

          -  Non-osteoporotic bone disease

          -  Recent fragility fracture within 6 months

        Control group:

        Inclusion Criteria:

          -  Women, men

          -  20-70 years of age

          -  Normal liver function (defined as liver function parameters and transaminases, such as
             albumin, thromboplastin time, alanine-aminotransferase, aspartate-aminotransferase,
             and gamma-glutamyl-transferase within the normal range)

        Additional exclusion Criteria:

          -  Osteoporosis according to BMD measurement or osteopenia plus fragility fracture

          -  Liver disease (defined as evidence of significant liver disease according to
             laboratory testing)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Katharina Kerschan-Schindl, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Vienna</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Katharina Kerschan-Schindl, MD</last_name>
    <phone>+436644301646</phone>
    <email>katharina.kerschan-schindl@meduniwien.ac.at</email>
  </overall_contact>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 5, 2018</study_first_submitted>
  <study_first_submitted_qc>January 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 16, 2018</study_first_posted>
  <last_update_submitted>March 20, 2018</last_update_submitted>
  <last_update_submitted_qc>March 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Katharina Kerschan-Schindl</investigator_full_name>
    <investigator_title>MD, Assoc professor</investigator_title>
  </responsible_party>
  <keyword>Bone microarchitecture</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
    <mesh_term>Liver Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

